medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 6

<< Back Next >>

Ann Hepatol 2016; 15 (6)

Predictive role BLVRA mRNA expression in hepatocellular cancer

Kubícková K, Subhanová I, Konícková R, Matousová L, Urbánek P, Parobková H, Kupec M, Pudil J, Vítek L

Language: Spanish
References: 44
Page: 881-887
PDF size: 230.85 Kb.


ABSTRACT

Introduction and aim. Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor. It is primarily caused by hepatic cirrhosis or chronic viral hepatitis. Hepatic carcinogenesis is associated with increased oxidative stress. Thus, the aim of our study was to assess expression of the genes involved in the homeostasis of oxidative stress in patients with HCC. Material and methods. The study was performed on 32 patients with primary HCC (verified by liver histology in 29 patients) and 27 control subjects (in 11 subjects, liver histology was available either with no or minimal changes in the liver tissue). Gene expressions of heme oxygenase 1 (HMOX1), biliverdin reductase A/B (BLVRA/B), NADPH oxidase 2 (NOX2) and p22phox were analyzed in the liver and peripheral blood leukocytes (PBL) in the subjects. Results. Compared to controls, almost a 3 times higher mRNA level of BLVRA was detected in livers of HCC patients (p = 0.002); while those of BLVRB as well as HMOX1 were unchanged (p › 0.05). In accord with these results in the liver tissue, BLVRA mRNA levels in PBL were also significantly increased in HCC patients (p = 0.012). mRNA levels of NOX2 and p22phox in the liver tissue, although higher in HCC patients, did not differ significantly compared to control subjects (p › 0.05). Nevertheless, NOX2 mRNA level in PBL was significantly higher in HCC patients (p = 0.003). Conclusions. BLVRA mRNA levels in the liver as well as in PBL are significantly higher in HCC patients most likely as a feedback mechanism to control increased oxidative stress associated with HCC progression.


REFERENCES

  1. Ferlay J, Shin R, Bray F, al. e. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10. Available at http://www.iarc.fr/en/media-centre/iarcnews/ 2010/globocan2008.php. Access: Feb 15, 2016.

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.

  3. Kew MC. Epidemiology of hepatocellular carcinoma in sub- Saharan Africa. Ann Hepatol 2013; 12: 173-82.

  4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.

  5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.

  6. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-S103.

  7. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.

  8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  9. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.

  10. Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2010; 52: 614-5.

  11. Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis 2001; 5: 109-22.

  12. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.

  13. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-21.

  14. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 2004: 76: 760-81.

  15. Lee YS, Kang YS, Lee JS, Nicolova S, Kim JA. Involvement of NADPH oxidase-mediated generation of reactive oxygen species in the apototic cell death by capsaicin in HepG2 human hepatoma cells. Free Radic Res 2004; 38: 405-12.

  16. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.

  17. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.

  18. Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets 2010; 11: 1551-70.

  19. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007; 43: 1-57.

  20. Cunningham O, Gore MG, Mantle TJ. Initial-rate kinetics of the flavin reductase reaction catalysed by human biliverdin-IXbeta reductase (BVR-B). Biochem J 2000; 345, Pt. 2: 393-9.

  21. O’Brien L, Hosick PA, John K, Stec DE, Hinds TD, Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab 2015; 26: 212-20.

  22. Lerner-Marmarosh N, Shen J, Torno MD, Kravets A, Hu Z, Maines MD. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci USA 2005; 102: 7109-14.

  23. Wegiel B, Baty CJ, Gallo D, Csizmadia E, Scott JR, Akhavan A, Chin BY, et al. Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem 2009; 284: 21369-78.

  24. Gibbs PE, Miralem T, Maines MD. Biliverdin reductase: a target for cancer therapy? Front Pharmacol 2015; 6: 119.

  25. Subhanova I, Muchova L, Lenicek M, Vreman HJ, Luksan O, Kubickova K, Kreidlova M, et al. Expression of biliverdin reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patients. PloS One 2013; 8: e57555.

  26. Choi J, Corder NL, Koduru B, Wang Y. Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med 2014; 72: 267-84.

  27. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005; 24: 367-80.

  28. Tsukiyama-Kohara K. Role of oxidative stress in hepatocarcinogenesis induced by hepatitis C virus. Int J Mol Sci 2012; 13: 15271-8.

  29. Crosas-Molist E, Bertran E, Fabregat I. Cross-Talk Between TGF-beta and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis. Curr Pharm Des 2015; 21: 5964-76.

  30. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, et al. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010; 25: 627-34.

  31. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005; 19: 1890-2.

  32. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, Takayanagi R. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78: 905-19.

  33. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, et al. Inhibition of heme oxygenase- 1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005; 11: 3790-8.

  34. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Rad Biol Med 2004; 37: 1097-104.

  35. Caballero F, Meiss R, Gimenez A, Batlle A, Vazquez E. Immunohistochemical analysis of heme oxygenase-1 in preneoplastic and neoplastic lesions during chemical hepatocarcinogenesis. Int J Exp Pathol 2004; 85: 213-21.

  36. De Giorgi V, Buonaguro L, Worschech A, Tornesello ML, Izzo F, Marincola FM, Wang E, et al. Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013;8: e56153.

  37. Arena V, Pennacchia I, Guerriero G, Mancuso C. The heme oxygenase/biliverdin reductase system in skin cancers. J Biol Regul Homeost Agents 2015; 29: 259-64.

  38. Maines MD, Mayer RD, Erturk E, Huang TJ, Disantagnese A. The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma-pH and cofactor-specific increase in activity. J Urol 1999; 162: 1467-72.

  39. Hellman K, Alaiya AA, Becker S, Lomnytska M, Schedvins K, Steinberg W, Hellstrom AC, et al. Differential tissue-specific protein markers of vaginal carcinoma. Br J Cancer 2009; 100: 1303-14.

  40. Melle C, Ernst G, Scheibner O, Kaufmann R, Schimmel B, Bleul A, Settmacher U, et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res 2007; 6: 306-15.

  41. Huan L, Bao C, Chen D, Li Y, Lian J, Ding J, Huang S, et al. MiR-127-5p targets the biliverdin reductase B/NF-kappaB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci 2016; 10.1111/cas.12869.

  42. Kim SY, Kang HT, Choi HR, Park SC. Biliverdin reductase A in the prevention of cellular senescence against oxidative stress. Exp Mol Med 2011; 43: 15-23.

  43. Miralem T, Hu ZB, Torno MD, Lelli KM, Maines MD. Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J Biol Chem 2005; 280: 17084-92.

  44. Kim SS, Seong S, Lim SH, Kim SY. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem Biophys Res Commun 2013; 440: 658-63.




2020     |     www.medigraphic.com